Subsequent studies have demonstrated an association between PTEN loss and poor clinical outcomes in cohorts ranging from 59 to 322 tumors samples, confirming that PTEN alterations confer substantial malignant potential to prostate cancer cells (24–26). This evidence concerns the gene PTEN and Familial prostate cancer.